Last updated: February 27, 2026
What Is the Drug Associated with NDC 59651-0256?
The National Drug Code (NDC) 59651-0256 corresponds to Fostemsavir, an antiviral medication approved by the FDA in July 2020. It is indicated for the treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to construct a suppressive regimen due to resistance, intolerance, or safety considerations.
Market Size and Demographics
Patient Population
- Total U.S. HIV-positive population: approximately 1.2 million.
- Estimated heavily treatment-experienced subset: 10-15% (~120,000 to 180,000).
- Patients with multidrug-resistant HIV: approximately 5-10%, estimated at 60,000 to 120,000.
Competitive Landscape
- Fostemsavir (brand: Rukobia) holds an orphan drug designation, targeting a niche sector.
- Limited competition: other drugs for resistant HIV include ibalizumab (Trogarzo), dolutegravir, and bictegravir, but few directly target that resistance profile.
- Market entry barriers: high development and manufacturing complexity.
Prescribing Trends
- Early adoption underway; prescriber awareness increasing among infectious disease specialists.
- Market penetration remains low but increasing, with gradual growth expected as awareness and indications expand.
Pricing Analysis
Current Wholesale Acquisition Cost (WAC)
- In 2023, the average wholesale price is approximately $35,000 to $40,000 per year per patient.
- The per-dose cost is roughly $F, based on dosing instructions, but proprietary data indicates a unit price of $250 to $300 per tablet.
Comparative Pricing
| Drug |
Indicated Population |
Annual Cost |
Cost per Patient |
Market Position |
| Fostemsavir |
Multidrug-resistant HIV |
$35,000-$40,000 |
$35k-$40k |
Niche, high-cost due to resistance profile |
| Ibalizumab |
Multidrug-resistant HIV |
$37,500-$45,000 |
$37.5k-$45k |
Parenteral, administered quarterly |
| Dolutegravir |
Broad HIV population |
$24,000 |
$2,000 (over 12 months) |
First-line therapy, more cost-effective |
Price Trends & Projections
- Short-term (1-2 years): Expect limited fluctuation in price, maintaining near current levels due to the drug’s niche status.
- Medium-term (3-5 years): Potential increase if indications expand or if supply constraints develop.
- Long-term (5+ years): Price may decrease with generic or biosimilar development, though current complex patent protections may delay generic entry.
Cost Drivers & Market Forces
- High R&D costs for targeting resistant HIV strains.
- Strict regulatory controls and limited manufacturing scale.
- Reimbursement policies leverage high-cost treatment as necessary for resistant populations.
- Competitive pressure from existing and emerging therapies.
Regulatory and Patent Outlook
- The patent for Fostemsavir extends through 2030, creating residual pricing power.
- Orphan designation confers market exclusivity, delaying generic competition.
- Ongoing clinical trials may support expanded labeling, influencing pricing.
Key Opportunities and Risks
Opportunities
- Expanding indication to broader resistant HIV populations.
- Partnership with health systems for preferential formulary placement.
- Use in combination regimens for multidrug-resistant cases.
Risks
- Price erosion from potential biosimilars or generics post-patent expiration.
- Competitive advances in alternative therapies.
- Changes in reimbursement policies or treatment guidelines.
Key Takeaways
- NDC 59651-0256 (Fostemsavir) is a niche HIV therapy with stable high-end pricing.
- Market size remains limited to heavily treatment-experienced, multidrug-resistant HIV patients.
- Price projections indicate stability short-term, potential inflation with indication expansion.
- Patent protections through 2030 support high margins, but long-term affordability may decline with biosimilar entry.
- The market is characterized by high costs driven by R&D, supply constraints, and limited competition.
FAQs
1. Will the price of Fostemsavir decrease after patent expiration?
Yes, generic competitors are likely to enter the market post-patent expiration, driving prices down. However, timeline projections suggest patent protections are active until at least 2030.
2. How does Fostemsavir compare to other HIV treatments in terms of cost?
It is significantly more expensive than first-line therapies like dolutegravir, reflecting its niche role in resistant cases.
3. Are there upcoming clinical trials that might influence the drug's market?
Ongoing trials aim to expand indications and improve formulations, which might affect pricing and market size.
4. What factors could further increase Fostemsavir's market share?
Indication expansion, increased provider awareness, and inclusion in treatment guidelines for resistant HIV could boost adoption.
5. How do reimbursement policies impact pricing?
Reimbursement frameworks generally favor high-cost therapies for resistant populations, supporting current price levels.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves fostemsavir for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. https://www.fda.gov/news-events/press-announcements/fda-approves-fostemsavir-heavily-treatment-experienced-adults-multidrug-resistant-hiv-1-infection
[2] IQVIA. (2023). HIV market analysis report.
[3] GoodRx. (2023). Fostemsavir (Rukobia) pricing and comparison metrics.
[4] FDA. (2023). Orphan Drug Designations and Approvals. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-designation
[5] MarketWatch. (2023). HIV drug market trends.
